UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 593

Sortiert nach

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

Journal of clinical oncology, 2019-08, Vol.37 (22), p.1927-1934

2019

Link zum Volltext

Verfügbarkeit prüfen

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-03, Vol.34 (8), p.879-881

Awad, Mark M

2016

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2369-2379

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

Clinical cancer research, 2016-12, Vol.22 (24), p.6051-6060

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting MET Dysregulation in Cancer

Cancer discovery, 2020-07, Vol.10 (7), p.922-934

2020

Link zum Volltext

Verfügbarkeit prüfen

False positive plasma genotyping due to clonal hematopoiesis

Clinical cancer research, 2018-09, Vol.24 (18), p.4437-4443

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2021-05, Vol.81 (9), p.2566-2573

2021

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

The lancet oncology, 2020-06, Vol.21 (6), p.786-795

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Cancer cell, 2020-01, Vol.37 (1), p.104-122.e12

2020

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Clinical cancer research, 2020-08, Vol.26 (15), p.4135-4142

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer cell, 2018-05, Vol.33 (5), p.853-861.e4

2018

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase gene rearrangements in epithelial malignancies

Nature reviews. Cancer, 2013-11, Vol.13 (11), p.772

2013

Link zum Volltext

Verfügbarkeit prüfen

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond

Clinical advances in hematology & oncology, 2014-07, Vol.12 (7), p.429-439

2014

Link zum Volltext

Verfügbarkeit prüfen

Imaging of Precision Therapy for Lung Cancer: Current State of the Art

Radiology, 2019-10, Vol.293 (1), p.15

2019

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Cancer immunology research, 2017-04, Vol.5 (4), p.312-318

2017

Link zum Volltext

Verfügbarkeit prüfen

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Journal of clinical oncology, 2016-03, Vol.34 (7), p.721-730

2016

Link zum Volltext

Verfügbarkeit prüfen

Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics

Journal of thoracic oncology, 2022-01, Vol.17 (1), p.154-159

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply to Kus and Aktas

Journal of thoracic oncology, 2022-06, Vol.17 (6), p.e64-e65

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Journal of clinical oncology, 2018-07, Vol.36 (19), p.1905-1912

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 593

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(546)
Mit Volltextzugriff
(529)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(316)
Life Sciences & Biomedicine
(283)
Humans
(212)
Oncology
(134)
Male
(106)
Female
(101)
Middle Aged
(73)
Aged
(67)
Mutation
(67)
Lung Neoplasms - Drug Therapy
(66)
Animals
(65)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(57)
Adult
(49)
Patients
(47)
Lung Neoplasms - Genetics
(46)
Mice
(46)
Immunotherapy
(42)
Lung Cancer
(42)
Carcinoma, Non-Small-Cell Lung - Genetics
(40)
Lung Neoplasms - Pathology
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

Targeting MET Dysregulation in Cancer

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

False positive plasma genotyping due to clonal hematopoiesis

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Tyrosine kinase gene rearrangements in epithelial malignancies

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond

Imaging of Precision Therapy for Lung Cancer: Current State of the Art

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics

Reply to Kus and Aktas

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Suchergebnisse filtern